Dasotraline
- Generic Name
- Dasotraline
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15Cl2N
- CAS Number
- 675126-05-3
- Unique Ingredient Identifier
- 4D28EY0L5T
- Background
Dasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder, and Adult Attention Deficit Hyperactivity Disorder.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
- Conditions
- Interventions
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT03231800
- Locations
- 🇺🇸
Avida Inc, Newport Beach, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸South Shore Psychiatric Services PC, Hingham, Massachusetts, United States
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02795637
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Dasotraline Binge Eating Disorder Extension Study
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 533
- Registration Number
- NCT02684279
- Locations
- 🇺🇸
Neuotrials Research, Inc., Atlanta, Georgia, United States
🇺🇸Boston Clinical Trials, Boston, Massachusetts, United States
🇺🇸Texas Center for Drug Development, Inc., Houston, Texas, United States
Dasotraline Binge Eating Disorder Study
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 319
- Registration Number
- NCT02564588
- Locations
- 🇺🇸
PCSD- Feighner Research, San Diego, California, United States
🇺🇸Capstone Clinical Research, Libertyville, Illinois, United States
🇺🇸Sunstone Medical Research, LLC, Medford, Oregon, United States
Dasotraline Pediatric Extension Study
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT02457819
- Locations
- 🇺🇸
Psychiatric Associates, Overland Park, Kansas, United States
🇺🇸Harmonex Neuroscience Research, Inc, Dothan, Alabama, United States
🇺🇸Clinical Trials group at the Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States
Dasotraline Pediatric ADHD Study
- Conditions
- Interventions
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT02428088
- Locations
- 🇺🇸
Gulfcoast Clinical Research, Fort Myers, Florida, United States
🇺🇸Neurobehaviorial Medicine Group, PLLC, Bloomfield Hills, Michigan, United States
🇺🇸Harmonex Neuroscience Research, Dothan, Alabama, United States
Dasotraline Adult ADHD Study
- Conditions
- Interventions
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 636
- Registration Number
- NCT02276209
- Locations
- 🇺🇸
Gulfcoast Clinical Research, Fort Myers, Florida, United States
🇺🇸Kennedy Krieger Institute, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Open-label Safety Study in Adults With ADHD
- Conditions
- Interventions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 724
- Registration Number
- NCT02160262
- Locations
- 🇺🇸
Premeir Psychiatric Research Institute, LLC, Lincoln, Nebraska, United States
🇺🇸Pillar Clinical Research, LLC, Dallas, Texas, United States
🇺🇸Family Psychiatry of the Woodlands, The Woodlands, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.